Purple Biotech’s Abstract On IM1240, Lead Tri-Specific Antibody From CAPTN-3 Platform, Accepted For Oral Presentation At 38th EORTC-NCI-AACR Symposium
Benzinga Newsdesk 3 weeks ago
News
Oral presentation: November 20, 2026 at 15:00 CETREHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company
Oral presentation: November 20, 2026 at 15:00 CET
REHOVOT, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer activity while minimizing toxicity, today announced the acceptance of an abstract on IM1240, the lead tri-specific antibody from its CAPTN-3 platform, for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain, on November 18-20, 2026.
Data evaluating IM1240 in treatment-resistant human tumor models, including its multi-arm mechanism of action and the contribution of NKG2A engagement, as well as pharmacokinetic and safety evaluation of CAPTN-3’s conditional CD3 masking approach, will be presented in a plenary session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy, and Oncological Sciences, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai.
More on PPBT
Benzinga
Purple Biotech Presents Preclinical Data On IM1240, Lead Capped Tri-Specific Antibody From CAPTN-3 Platform, In Plenary Oral Session At 38th EORTC-NCI-AACR SymposiumPlenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against…
